the highest potential of successful stem cell therapy exists in spinal cord injury (SCI):

Hard to Treat Diseases Inc. (HTDS.PK) Participates in the Symposium "Stem Cells and Neuroregeneration"


HAARLEM, Netherlands and BELGRADE, Serbia, Feb. 10 /PRNewswire-FirstCall/ - Slavica Biochem (http://www.slavicabiochem.com), registered subsidiary of Hard to Treat Diseases (http://www.htdsmedical.com) is pleased to announce that two members of its scientific team, Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer and Dr. Ivana Gadjanski, communication director, participated in the "Stem Cells and Neuroregeneration" Symposium, held in Haarlem, the Netherlands on Feb 5 - 6, 2010.
The Symposium was organized under the auspices of the European Cooperation in the Field of Scientific and Technical Research (COST), action B30 in which Dr Sanja Pekovic is a permanent member as a represenative of Serbia. Main topic of the Symposium was the potential therapeutical use of neural stem cells for neurodegenerative disorders. As summarized in the lecture by Dr. Zaal Kokaia, Professor of Neuroscience from the Stem Cell Centre, Lund, Sweden, the highest potential of successful stem cell therapy exists in spinal cord injury (SCI), amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease), Parkinson's disease (PD), multiple sclerosis (MS) and stroke.
This was an important event for HTDS, its research team and its management as the company continues to explore the options of commencing its own stem cell bank project together with the continuation of the due diligence stage with the potential merger candidates; engaged in the treatment of pre-term labor and induction of labor and other aspects of regenerative medicine.

Furthermore, very interesting was a lecture by Dr. Chris Airriess, "Towards an FDA approved trial for ES cell repair in spinal muscular atrophy". Their work is currently in the pre-clinical development stage of stem cell based therapies for ALS, spinal muscular atrophy (SMA), spinal cord injury (SCI) and coronary heart disease. The end result they aim for is to perform the world's first human embryonic stem cell therapy.

A special focus during the Symposium was put on induced pluripotent stem cells and their potential clinical applications, by Dr. Sjef Copray, Associate Professor, Department Neuroscience, UMCG, Groningen, the Netherlands who was also one of the organizers of the Symposium. The lectures presented during the Symposium summarized recent advances in stem cell research and their future application in regenerative medicine, as well as the hurdles that still need to be overtaken before safe clinical application.
In other company events and news, as the company no longer subscribes to Pink Sheets filing services all company filings, non news worthy events, financial statements and similar will be posted on the companys own corporate web site www.htdsmedical.com and on its IR firms www.minamargroup.net web site (CLICK ON CLIENT SUPPORT TAB) or visit this direct link http://minamarmarketinggroup.helpserve.com/.
To be included in HTDS' email database for press releases and industry updates, please subscribe at or opt in with your email address at this link: http://www.minamargroup.net/updates
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiries only, please contact medicalinfo@htdsmedical.com; for any corporate matters, please contact www.minamargroup.net/helpdesk
http://www.prnewswire.com/news-relea...-84023242.html